Puerto Rico Manufacturing Proposition Analysis
As expected, Puerto Rico has best chance to attract volumes in current areas
of strength, which informs recommended company prioritization
Existing
footprint
Biopharma
Small Molecules, and some Biologics
-80% of pharma products identified as made in PR are
small molecules, compared with -50% of US sales¹
"PR has a history of a high level of competency
small molecules; some I believe in biologics too
- VP of Manufacturing, large generics co
"We are seeing a move in PR towards biopharma
products and processes in the oral solid dosage
area finishing and packaging and less in APIs
- CRB Caribe, HC&LS Review
"Vaccines will need capacity, but also high risk
and would want to go where the skill set exists
- VP of Global Supply Business Dev., large pharma
New modalities are very complex so they
require very skilled operators, high speed, high
quality, and extensive experience
No / limited
footprint
"
- Director of Mfg for Gene Therapy, large pharma
Medtech
Products that require highly technical, or manual
technology-enabled manufacturing are a good fit to
Puerto Rico's value proposition
- VP of Operations, large medtech
"PR is an extremely attractive option from a med
tech standpoint, especially because quality and
reliability are on par with other US locations
66
- Former Global Head of Procurement, large medtech
Approximately 60% of consumables are already made in
the US today; PR does have some mid-volume products
like tubing sets but most high-volume consumables, like
needles, are made in the South of the US
- Director of Global Strategic Sourcing, large medtech
High end instrumentation used to be the sweet spot
for the US, but no longer...much of this is moving to Asia
VP Former Global Head of Procurement, large medtech
1. Based on analysis of 125 identified pharma products with at least one manufacturing step in Puerto Rico; US sales in terms of dollar value
Source: PharmNets, Evaluate Pharma, Health and Life Sciences Review Puerto Rico 2016, Expert interviews, BCG analysis
Copyright © 2020 by Boston Consulting Group. All rights reserved.View entire presentation